Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation

Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation

Chimeric antigen receptor T cell (CAR-T) therapy demonstrated remarkable success in long-term remission of cancers and other autoimmune diseases. Currently, six products (Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti) are approved by the US-FDA for treatment of a few hematological mali...

Full description

Bibliographic Details
Main Authors: Aalia N. Khan, Ambalika Chowdhury, Atharva Karulkar, Ankesh Kumar Jaiswal, Ankit Banik, Sweety Asija, Rahul Purwar
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Immunology
Subjects:
chimeric antigen receptor
monoclonal antibodies
scFv
cellular immunity
anti-CAR antibodies
persistence
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.886546/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.886546/full

Similar Items